Compare Ascendis Pharma A/S (ASND) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Ferrari NV — how do they compare? Ascendis Pharma A/S trades at $263.66 (market cap $17.74B), while Ferrari NV trades at $377.53 (market cap $66.31B). The key difference: Ferrari NV is far larger — about 3.7× Ascendis Pharma A/S's market cap, and Ferrari NV pays a 1.12% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | RACE | |
|---|---|---|
Market Cap | $17.74B | $66.31B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $517.65 |
52-Week Low | $163.32 | $314.63 |
Enterprise Value | $18.11B | $67.52B |
Dividend Yield | — | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Ferrari (RACE) trades at $376.64, up 0.53% with bullish technical signals and strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.73 exceeding expectations. Revenue grew to $7.15B in 2025, supported by a 22.19% net margin and 41.96% ROE. Recent news highlights include a new EV model launch and ongoing share buybacks, while technical indicators point to support near $372 and resistance at $377.
The outlook remains positive with a consensus price target of $467.50, implying 24% upside. Key risks include execution challenges with new electric vehicles and economic sensitivity. Analyst sentiment is strongly bullish (72% buy ratings), but investors should monitor competitive pressures and margin sustainability amid hybrid transition efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
